Forest Laboratories Reports Fiscal Fourth Quarter 2005 Results and
Provides Earnings Per Share Guidance for Fiscal 2006 NEW YORK,
April 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE:FRX), an international pharmaceutical manufacturer and
marketer, today reported revenues and earnings for its fiscal
fourth quarter and twelve months ended March 31, 2005. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Fourth
Quarter Results Net sales for the quarter decreased 15% to
$618,285,000 from $725,080,000 in the prior year's fourth quarter
as a result of the launch of generic equivalents of the Company's
antidepressant Celexa(R) (citalopram HBr). Sales in the current
quarter included $406,432,000 for Forest's antidepressant franchise
which was comprised of $399,381,000 of Lexapro(R) (escitalopram
oxalate), $6,197,000 of Celexa, and $854,000 of generic citalopram,
all selective serotonin reuptake inhibitors (SSRIs). Antidepressant
sales in last year's fourth quarter were $597,493,000 consisting of
$351,838,000 of Lexapro and $245,655,000 of Celexa. Sales of
Namenda(R), a NMDA receptor antagonist for the treatment of
moderate to severe Alzheimer's disease, were $93,945,000 compared
to $34,295,000 in the year ago quarter. Earnings from the co-
promotion agreement with Sankyo Pharma for Benicar(R)* and Benicar
HCT(TM), antihypertensive therapies, totaled $21,329,000 in the
current quarter. Net income in the current quarter decreased 64% to
$52,755,000, or $0.15 per share, as compared to net income of
$145,482,000, or $0.38 per share, in the fourth quarter of the
prior year. Net income in the quarter was reduced by a one-time
special charge of $91 million, or $0.25 per diluted share
outstanding, related to taxes associated with $1.239 billion of
funds repatriated under the American Jobs Creation Act of 2004.
Excluding the one- time charge, earnings per share would have
equaled $0.40. Selling, general and administrative expenses
decreased 11% from last year's fourth quarter to $266,459,000.
Research and development spending decreased 23% to $61,758,000
during the quarter. Research and development expense in the year
ago quarter included upfront payments, including a payment of $25
million to Cypress Bioscience, Inc. for the signing of a
development and marketing agreement for milnacipran. During the
quarter Forest repurchased an additional 7.8 million shares under
its exiting share repurchase program increasing the program-to-date
total to 23.9 million shares. The Company continues to have an
additional 6.1 million shares available for repurchase under the
existing 30 million share authorization. Twelve Months Results Net
sales for the fiscal year ended March 31, 2005 increased by 15% to
$3,052,408,000 from reported net sales of $2,650,432,000 in fiscal
2004. For the fiscal year, total antidepressant franchise sales
were $2,263,310,000 which was comprised of $1,605,296,000 of
Lexapro, $653,450,000 of Celexa and $4,564,000 of generic
citalopram. Antidepressant franchise sales in fiscal 2004 were
$2,176,238,000 which was comprised of $1,088,957,000 of Lexapro and
$1,087,281,000 of Celexa. Net sales of Namenda were $332,707,000
for fiscal 2005 versus $45,472,000 for fiscal 2004. Net income for
the twelve months ended March 31, 2005 increased 14% to
$838,805,000 from net income of $735,874,000 reported in the prior
year. Excluding the one-time $91 million tax charge, net income
increased 26% to $929,462,000 from net income of $735,874,000 in
the prior year. Selling, general and administrative expenses
increased 12% to $993,715,000, while research and development
spending increased 19% to $293,659,000 during the year. Diluted
earnings per share for fiscal 2005 equaled $2.25 compared to
diluted earnings per share of $1.95 in fiscal 2004 and would have
been $2.50 excluding the one-time tax charge. Fiscal 2006 Guidance
Regarding the fiscal year ending March 31, 2006, the first full
fiscal year with generic competition for Celexa, the Company
expects that fully diluted earnings per share will be approximately
$2.30. Forest projects that quarterly earnings per share in the
fiscal first quarter of 2006 will be higher than reported earnings
per share in the fiscal fourth quarter of 2005 and that quarterly
earnings per share will show sequential growth through fiscal 2006.
The Company anticipates that net sales for the year will be
approximately $50 million lower than the $3,052,408,000 reported in
fiscal 2005 but that net revenue, which includes the earnings
contribution from Benicar, interest income and other income will
increase slightly from reported net revenue in fiscal 2005 of
$3,159,639,000. Forest anticipates continued growth in revenue for
its three principal marketed products, Lexapro, Namenda and
Benicar, as well as revenue contribution from our two recently
launched products, Campral(R) for the maintenance of abstinence
from alcohol in patients with alcohol dependence who are abstinent
at treatment initiation and Combunox(TM) for the short-term
management of acute moderate to severe pain. Campral and Combunox
will reduce earnings in fiscal 2006 during their launch phase but
should contribute to earnings in the future. Key assumptions
supporting the fiscal year forecast include the following: For
Lexapro, a projected decline in overall prescription volume for the
underlying SSRI/SNRI antidepressant market as a whole of
approximately 0.5% and an increase in Lexapro's total prescription
market share from 19.7% at March 31, 2005 to approximately 21.5% at
March 31, 2006. This increase in market share along with a price
increase should generate Lexapro sales of slightly less than $2
billion. Namenda is also expected to increase its total
prescription volume and benefit from a projected underlying
prescription volume growth for the Alzheimer's market in the 11%
range. We anticipate that Namenda sales should be approximately
$530,000,000 for the fiscal year. The Company expects that Benicar
will continue to show strong market share gains in fiscal 2006 in a
market that will continue to show low double-digit growth. Earnings
from Benicar in fiscal 2006 are expected to more than double from
fiscal 2005. For purposes of this forecast the Company is not
factoring in any increase in inventory levels at key wholesaler and
chain customers but rather anticipating that current levels of
approximately two weeks supply will be an average level throughout
our fiscal year. The fiscal 2006 projection includes an approximate
10% increase in selling, general and administrative expenses which
would imply spending near the $1.1 billion level. Research and
development spending is expected to increase by approximately 25%
during the year to $365,000,000 to support numerous clinical
development programs and account for potential milestone payments
as these programs progress. The estimate does not include upfront
payments, milestone or research payments for new products the
Company may license during the fiscal year. Howard Solomon,
Chairman and Chief Executive Officer of Forest, said: "Fiscal 2005
demonstrated Forest's ability to replace lost profits from Celexa
by continuing to successfully position our key products, Lexapro,
Namenda and Benicar in the marketplace. During the just completed
fiscal year, all of our principal promoted products increased their
prescription market share and continue to be viewed by physicians
as important treatments for their respective disease states. In
addition, our business development group successfully completed
development agreements with three new partner companies for three
new product candidates. We believe that our pipeline includes
promising product opportunities and we continue to look forward to
entering into additional development agreements." Mr. Solomon
continued: "For fiscal 2006, although quarterly earnings per share
comparisons will be more difficult earlier in the year, the Company
is on track to generate meaningful earnings per share despite the
availability of generic Celexa. During the year our salesforce will
focus on maximizing the in-market potential of our currently
promoted products while our Research Institute will continue to
progress on its development programs." Mr. Solomon added: "The
Lexapro patent infringement case is expected to proceed on schedule
with a May 9, 2005 trial date. Forest remains confident in the
strength of the Lexapro patent." Forest Management will host a
conference call at 10:00 AM EDT today to discuss the results. The
conference call will be webcast live on the Company's website at
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until April 30, 2004 at both
websites and also by dialing 1 800 642 1687 (US investors) or +1
706 645 9291 (international investors) passcode 5519975. About
Forest Laboratories and Its Products Forest Laboratories' growing
line of products includes: Lexapro(R) (escitalopram oxalate), an
SSRI antidepressant indicated for the initial and maintenance
treatment of major depressive disorder and for generalized anxiety
disorder in adults; Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker indicated
for the treatment of hypertension; Benicar* HCT(R) (olmesartan
medoxomil hydrochlorothiazide), an angiotensin receptor blocker and
diuretic combination product indicated for the second-line
treatment of hypertension; Campral(R)* (acamprosate calcium), a
glutamate receptor modulator, indicated for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation in combination with psychosocial
support; and Combunox(TM) (Oxycodone HCl and Ibuprofen), an opioid
and NSAID combination indicated for the short-term management of
acute, moderate to severe pain. Except for the historical
information contained herein, this release contains
"forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA
approvals, acceptance and demand for new pharmaceutical products,
the impact of competitive products and pricing, the timely
development and launch of new products and the risk factors listed
from time to time in the Company's SEC reports, including the
Company's Annual Report on Form 10-K for the fiscal year ended
March 31, 2004, and on form 10-Q for the periods ended June 30,
September 30, and December 31, 2004. * Benicar is a registered
trademark of Sankyo Pharma, Inc., and Campral is a registered
trademark under license from Merck Sante s.a.s., subsidiary of
Merck KGaA, Darmstadt, Germany. FOREST LABORATORIES, INC. AND
SUBSIDIARIES CONSOLIDATED STATEMENT OF INCOME THREE MONTHS TWELVE
MONTHS ENDED MARCH 31 ENDED MARCH 31 (In thousands, except per
share amounts) 2005 2004 2005 2004 Revenues: Net sales $618,285
$725,080 $3,052,408 $2,650,432 Contract revenue 22,313 687 61,369
5,810 Other income 12,638 7,372 45,862 24,032 Net revenues 653,236
733,139 3,159,639 2,680,274 Costs and expenses: Cost of goods sold
142,212 169,105 687,510 608,474 Selling, general and administrative
266,459 298,112 993,715 888,517 Research and development 61,758
80,713 293,659 246,461 470,429 547,930 1,974,884 1,743,452 Income
before income tax expense 182,807 185,209 1,184,755 936,822 Income
tax expense 130,052 39,727 345,950 200,948 Net income $ 52,755
$145,482 $838,805 $735,874 Net income per share: Basic $0.15 $0.39
$2.30 $2.01 Diluted $0.15 $0.38 $2.25 $1.95 Weighted average number
of shares outstanding : Basic 351,023 368,537 363,991 365,447
Diluted 356,989 381,088 372,090 376,779
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President - Investor Relations of Forest Laboratories, Inc,
+1-212-224-6714 Web site: http://www.frx.com/
http://www.streetevents.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2023 to Aug 2024